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Transcranial Doppler can detect microembolic signals which are characterized by unidirectional high intensity increase, short
duration, random occurrence, and a “whistling” sound. Microembolic signals have been detected in a number of clinical settings:
carotid artery stenosis, aortic arch plaques, atrial ﬁbrillation, myocardial infarction, prosthetic heart valves, patent foramen
ovale, valvular stenosis, during invasive procedures (angiography, percutaneous transluminal angioplasty), surgery (carotid,
cardiopulmonary bypass, orthopedic), and in certain systemic diseases. Microembolic signals are frequent in large artery disease,
less commonly detected in cardioembolic stroke, and infrequent in lacunar stroke. This article provides an overview about the
current state of technical and clinical aspects of microembolus detection.
1.Introduction
1.1. Clinical Aspects. Acute stroke is one of the leading cause
of morbidity and mortality worldwide. In developed coun-
tries, stroke ranks as either second or third most common
cause of death and embolization is the cause of ischemic
stroke in 40%–80% of cases [1]. TCD is a sensitive technique
for real-time detection of microembolic signals (MESs). In
the last 20 years, a substantial number of studies dealing
with emboli detection have been carried out, showing that
MES are proven to represent emboli passing within cerebral
circulation. MES have been detected in a number of clinical
conditions: carotid artery stenosis, aortic arch plaques, atrial
ﬁbrillation, myocardial infarction, prosthetic heart valves,
patent foramen ovale, valvular stenosis, during carotid sur-
gery, surgery on open heart, stent implantation, percuta-
neous transluminal angioplasty and angiography, and in
patients with migraine and patent foramen ovale (PFO).
Patients who have detectable MES, especially in larger num-
ber, should be considered as high-risk patients for stroke.
MES detection may help in localization of embolic source,
identiﬁcation of patients with high stroke risk, monitoring
during invasive procedures and surgery, and monitoring of
the eﬀectiveness of therapy.
Consensus on MES detection by TCD has been estab-
lished [2]; MES can be identiﬁed as short lasting (<0.01–
0.03s), unidirectional intensity increase, and intensity in-
crease (>3dB) within the Doppler frequency spectrum; in-
tensity increase is focused around 1 frequency. MESs appear
randomly within the cardiac cycle and produce a “whistle,”
“chirping,” or “clicking” sound when passing through the
sample volume.
1.2.TechnicalAspects. TCDisaveryconvenienttooltomon-
itor intracranial circulation, however, the thick temporal
bone window is an obstacle in certain patients. A new tran-
scranial modality, power M-mode Doppler (PMD), has been
developed to overcome the diﬃculties in location and inso-
nation through transcranial ultrasound windows. PMD has
33 sample gates placed with 2mm spacing for display of
Dopplersignalpower,coloredredandbluefordirectionality,
in an M-mode format. The spectrogram from a user-selected
depth is displayed simultaneously. PMD facilities window
locationandalignmentoftheultrasoundbeamtoviewblood
ﬂow from multiple vessels simultaneously, without sound or
spectral clues. MES appear as characteristic sloping high-
p o w e rt r a c k si nt h eP M Di m a g e[ 3, 4].2 Stroke Research and Treatment
The optimal time of monitoring depends on the clinical
entity. In patients with implanted artiﬁcial heart valves in
whom MES can be detected in large proportion, monitoring
during 30 minutes will be suﬃcient. In patients with carotid
artery stenosis, atrial ﬁbrillation, or other cardiac disease,
frequency of MES is usually low, 1-2MES over 60 minutes.
Extended monitoring up to 8 hours, or repetitive monitoring
ov erac oupleofda ysinsuccession,isinr elationwiththeper -
centage of MES positive patients [5, 6]. The embolic activity
is highest in the ﬁrst couple of hours after stroke; however,
MES may be detectable days and weeks after cerebrovascular
incidents which means that those patients are under higher
risk for stroke [7–11].
Although technological improvement in the area of MES
detection has recently developed, it is still impossible to
reliably distinguish the composition of emboli (particles of
fat, platelet aggregates, or particles of atheroma). Diﬀer-
entiation between solid and gaseous microemboli is based
on the principle that solid emboli reﬂect more ultrasound
at higher frequency, whereas the opposite is the case for
gaseous emboli. This principle is used in multifrequency
TCD instrumentation where the vessels are insonated simul-
taneously with 2.5 and 2.0MHz and can be used for the
diﬀerentiation between gaseous and solid emboli [12]. A
recent study has shown that there is a signiﬁcant relationship
between low- and high-intensity MES, indicating that many
MESsroutinelyrejectedbecauseoftheirlowintensityarereal
and may predict future occurrence of high-intensity MES
[13].
2.ClinicalCondition inWhichMES
May Be Detected
2.1. Atherosclerotic Disease
2.1.1. Carotid Stenosis. Carotid artery stenosis is a well-
known source of cerebral MES [7, 8, 14–19]. Systematic
review of the literature showed that MES can be detected in
43% of patients with symptomatic and in 10% with asymp-
tomatic carotid stenosis; presence of one MES indicated an
increased risk of future events (OR 7.5, 95% conﬁdence
interval (CI): 3.6–15.4, P<0.0001 for symptomatic and
OR 13.4, 95% CI: 6.5–27.4, P<0.0001 for asymptomatic
disease) [20]. A meta-analysis of the literature revealed that
MESs are most frequent in large artery disease, less frequent
in cardioembolic stroke, and infrequent in lacunar stroke.
For symptomatic carotid stenosis, ES predicted stroke alone
(OR,9.57;P = 0.02)andstroke/TIA(OR,6.36;P<0.00001).
For asymptomatic carotid stenosis, ES predicted stroke alone
(OR,7.46;P = 0.001)andstroke/TIA(OR,12.00;P = 0.002)
but with heterogeneity (P = 0.004). In acute stroke, ES pre-
dictedstrokealone(OR,2.44;P = 0.02)andstroke/TIA(OR,
3.71; P = 0.002). A high frequency of ES immediately after
carotid endarterectomy predicted stroke alone (OR, 24.54;
P<0.00001) and stroke/TIA (OR, 32.04; P<0.00001). The
meta-analysis suggests that MES predict stroke risk in acute
stroke, symptomatic carotid stenosis, and postoperatively
after carotid endarterectomy; however, in asymptomatic
carotid stenosis, the predictive value of MES is less clear [21].
In the asymptomatic carotid emboli study (ACES), a
prospective observational study, patients with asymptomatic
carotid stenosis of at least 70% were monitored by TCD; the
results showed that the hazard ratio for the risk of ipsilateral
stroke and transient ischaemic attack from baseline to 2
years in patients with MES compared with those without was
2.54 (95% CI 1.20–5.36; P = 0.015). For ipsilateral stroke
alone, the hazard ratio was 5.57 (1.61–19.32; P = 0.007).
The absolute annual risk of ipsilateral stroke or transient
ischaemic attack between baseline and 2 years was 7.13%
in patients with MES and 3.04% in those without, and for
ipsilateral stroke was 3.62% in patients with MES and 0.70%
in those without [22].
Studies have shown that intraluminal thrombosis, irreg-
ular plaque surface, and ulceration are in relation with
emboli frequency [23–25]. Carotid plaque inﬂammation is
associated with cerebral microembolism in patients with
recent transient ischemic attack or stroke [26].
Despite optimum standard antiplatelet therapy, cerebral
microembolisation occurs in 30% of patients with symp-
tomatic carotid artery disease [27]. Patients with sympto-
matic high-grade ICA stenosis and who were on antiplatelet
treatment underwent bilateral MES monitoring for 30
minutes. The study has shown that the presence of MES is
independent of intrastenotic blood ﬂow disturbances and
gray-scale ultrasound plaque characteristics. The authors
concluded that the presence of MES is an indicator of an
unstable plaque [27].
Carotid plaques in patients with severe unilateral carotid
restenosisatleastoneyearaftersurgeryaresimilartopatients
with primary severe stenosis in their embolic potential and
ultrasonic characteristics [28].
Dissection of carotid arteries is an embolic source and
MES in those patients can be detected in a high proportion
[29]. Among patients with cervical artery dissection present-
ing with TIA or stroke, 50% had MES compared with 13% of
patients with local symptoms (P = 0.006) [20].
2.1.2. Aortic Arch Atheroma. Aortic arch atheroma has long
been underestimated as an embolic source. Studies have
shown that severe atheroma of the aortic arch has now been
established as an important and independent risk factor
for stroke. The prevalence of severe arch atheroma among
patients presenting with acute ischaemic stroke is approxi-
mately 20%.
The odds ratio for stroke or peripheral embolism in pa-
tients with severe arch atheroma (>4mm) is greater than
four, and for mobile atheroma it is greater than twelve, par-
ticularly in patients with other stroke risk factors. Patients
found to have severe atheroma are at high risk of recurrent
events (14.2% per year) and may, therefore, need an aggres-
sive secondary prevention strategy [19, 20].
2.1.3. Intracranial Stenosis. Intracranial stenosis is a signif-
icant source of cerebral emboli, although in most studies
not appreciated as important as carotid stenosis. A recent
study has shown that MESs were reported in 25% of 220
patients with symptomatic versus 0% of 86 patients with
asymptomatic intracranial stenosis (P<0.0001) [20].Stroke Research and Treatment 3
2.1.4. Thrombolysis and MES Occurrence. Thrombolysis is a
well-established therapy in acute stroke. TCD has proven to
serveasanenhancementtoolinclotdissolution.MESdetect-
ed by TCD at the site of arterial obstruction can indicate clot
dissolution and recanalization of intracranial arteries, and
therefore serve as a predictor for outcome [30].
2.1.5. Carotid Endarterectomy (CEA), Carotid Artery Stenting
(CAS), and Percutaneous Transluminal Angioplasty (PTA).
After carotid endarterectomy, MESs disappear or the fre-
quency is signiﬁcantly lower [31, 32]. However, patients with
clinically signiﬁcant postoperative microembolism have an
approximately 15 times higher risk of ipsilateral stroke or
TIA [33]. Eﬃcacy of CEA largely depends on postoperative
results, that is, perisurgical complications. Intraoperative
monitoring of hemodynamic changes and detection of MES
may signiﬁcantly inﬂuence postsurgical outcome [34]. Dif-
ferent antiplatelet regimens (combination of dipyridamole,
aspirin and clopidogrel) following CEA does not show a sig-
niﬁcant inﬂuence on postoperative TCD embolization [35].
However, administration of dual antiplatelet therapy (clopi-
dogrel 75mg plus aspirin 75mg) prior to CEA reduces post-
operative embolisation and thromboembolic events [36].
Meta-analysis of trials to date shows that symptomatic
and asymptomatic CAS patients had signiﬁcantly higher 30-
day postprocedure incidence of death/stroke/MI when com-
pared with CEA patients [37, 38].
Experimental studies have shown that during PTA, the
majority of MESs are gaseous in origin, while MESs detected
during balloon inﬂation are probably attributable to solid
particles [39].
The use of cerebral protection devices appears to reduce
thromboembolic complications during PTA and stenting.
T h ec o m b i n e ds t r o k ea n dd e a t hr a t ew i t h i n3 0d a y si np a -
tientstreatedwithcerebralprotectiondeviceswas1.8%com-
pared with 5,5% in patients without [40].
2.1.6. Angiography. MESs detected during angiography are
attributable to gas bubbles, contrast injection, clot formation
in catheter, and disrupted atheromatous material [41, 42].
Magnetic resonance studies have shown increased number
of brain parenchymal lesions after angiography, although
the majority of patients had nor neurological deﬁcit [43].
However, angiography of the aortic arch is associated with
1% risk for stroke with permanent deﬁcit, and in 3% mild-
t o - m o d e r a t es t r o k eo rT I A[ 41, 42]. In a study with 24
patients undergoing angiography, all had detectable MES,
approximately 51 per patient. The majority of MES had
the characteristics of gas bubbles. The number of detected
MESs correlated with the volume of injected contrast and all
patients except one who had stroke were asymptomatic [42].
2.2. Cardiac Sources. Approximately 15–30% of strokes are
caused by cardiac diseases [44]. Prospective studies have
shown that recurrent stroke or systemic embolization in that
group of patients is high, approximately 20% [7, 45].
2.2.1. Atrial Fibrillation. Atrial ﬁbrillation (AF) is present
in 1,7% of population aged 60–64 years, and in 6% of
population older than 75 years [46]. Incidence of stroke in
patients with AF is 4,5% per year [47]. In cases when AF
is associated with mitral valve stenosis, risk of stroke is 17
times higher [48]. Majority of strokes in patients with AF are
embolic in origin; MES can be detected in 15–30% [49, 50].
2.2.2. Patent Foramen Ovale. The prevalence of patent fora-
men ovale (PFO) in common population is 22–34.4% [51,
52]. In patients with cryptogenic stroke, especially younger
patients, a high prevalence of PFO has been found [53, 54].
The rate of recurrent stroke or TIA is 9.9% [55]. A mul-
ticentric study has shown that stroke risk over 4 years is
5,6% in patients with isolated PFO and 19,2% in patients
with PFO and atrial septal aneurysm (ASA) [56]. However, a
prospective population-based study has established that PFO
is not an independent risk factor for stroke when age and
comorbiditiy are considered [57].
A connection between migraine (especially migraine
with aura), stroke, and PFO has been established [58–63].
Studies have shown that the prevalence of PFO in patients
with migraine is about 2.5 times greater in comparison with
patients who do not suﬀer from migraine [64, 65]. Patients
with migraine with aura have twice as high risk for stroke.
Patients with probable migraine are 1, 5 times higher risk.
If female patients with migraine smoke and take oral con-
traceptives, the risk increases up to seven times compared to
those who do not have migraine [66–68].
According to one of the proposed hypothesis, paradoxal
embolization causes segmental hypoperfusion and vasodi-
latation, that is, PFO enables vasoactive substances (hypo-
theticaly serotonin) and microemboli from venous circula-
tion to pass the pulmonal ﬁlter (normally they would be
stopped in lungs), and entering the brain they can induce
cortical spreading depression which characterizes migrain-
ous attack [69]. This hypothesis could explain the decrease
of migraine prevalence and intensity after PFO closure (in
most studies). In favor of microembolization as a provoking
factor speaks the MRI study in which a 13.7 times higher
incidence of white matter lesions has been found in patients
with migraine with aura compared to brains of controls
[70–72]. Furthermore, most TCD studies have shown that
most paradoxical MES can be detected in posterior brain
circulation[70],whichisinterestingbecauseinthesepatients
PFO and migraine are more frequently present. However, up
to now, there is no deﬁnite evidence for proposed theories
regarding migraine onset caused by circulating microemboli.
2.2.3. Prosthetic Heart Valves. Thromboembolism is a signif-
icant complication in patients with prosthetic heart valves
(PHV).MEScanbedetectableincerebralcirculationranging
from 50 to 90% [73–75]. The majority of HITS in patients
with PHV correspond to gaseous, for example, due to cav-
itations at mechanical heart valves [76].
2.2.4. Myocardial Infarction. Approximately 2.5% of patients
withacutemyocardialinfarction(MI)willhavestrokewithin
2–4 months [77]. In a prospective study in patients with
anterior wall MI, MES could be detected in 21% [78].4 Stroke Research and Treatment
2.2.5. Infective Myocarditis. T h ep r e v a l e n c eo fs t r o k ei np a -
tients with infective myocarditis is 15–20% [79] .T h es i z eo f
vegetations has a predictive value: risk for embolization is
higher in patients with vegetations larger than 10mm, in pa-
tients with endocarditis of the mitral valve and mobile vege-
tations [79].
2.2.6. Dilatative Congestive Myocardiopathy. Incidence of
embolic complications in patients with cardiomyopathy is
4%peryear[78].MESsaredetectableinonethirdofpatients
with dilatative congestive myocardiopathy [44].
2.2.7. Mitral Valve Prolapse. Prevalence of mitral valve pro-
lapse (MVP) in common population is 1–15% [80]. Isolated
MVPisnotconsideredasasigniﬁcantriskfactorforstrokein
older patients, but in younger patients myxomatous change
of mitral valves is considered to be in relationship with cere-
brovascular incidents [80].
2.2.8. Cardiac Tumors. Although rare, atrial myxoma is the
most frequent primary cardiac tumor, usually present in the
left atrium. Due to its fragile nature, myxoma has a high po-
tentialforembolizationtothebrainaswellastootherorgans
[81].
2.2.9. Systemic Diseases. MESs in cerebral circulation are de-
tectable in primary antiphospholipid syndrome, Sneddon’s
syndrome, systemic lupus, Behcet’s disease, and Takayasu’s
arteritis and are in temporal relation with cerebrovascular
incidents in those patients [82–85].
2.2.10. Coagulation. Clinical studies have shown that hyper-
ﬁbrinogenemia is in a positive correlation with cardiovascu-
lar and cerebrovascular diseases [86–88]. Patients with pro-
gressive atherosclerosis have higher levels of ﬁbrinogen com-
pared with those with nonprogressive disease [89].
3. Monitoring of Therapeutic Efﬁcacy
Monitoring of therapeutic eﬀect has shown that after CEA,
MESs disappear or decrease in frequency, this ﬁnding is
consistent through studies [31, 32]. Studies that investigated
the eﬃcacy of anticoagulant and antiaggregation therapy
and frequency of MES have shown various results. Although
some studies have shown decrease in MES frequency after
aspirin or heparin administration, consistent correlation has
not been found [90].
Theﬁrstmulticenter,randomized,double-blindtrialthat
used MES detection as an endpoint to evaluate antiplatelet
therapy,theClopidogrel(CARESSandAspirinforReduction
of Emboli in Symptomatic Carotid Stenosis) trial, has shown
that clopidogrel plus aspirin is superior to aspirin alone
in reducing the frequency of MES in patients with recent
symptomatic carotid stenosis [91]. Glycoprotein IIb/IIIa re-
ceptor antagonist tiroﬁban is a highly selective platelet ag-
gregation inhibitor. Administration of tiroﬁban resulted in
microembolic rate drop down to zero in patients with severe
carotidarterystenosisintwostudies.However,theinhibitory
eﬀe c to ft i r o ﬁ b a ni sr e v e r s i b l e[ 92, 93].
4.ClinicalSigniﬁcanceofEmboli Detection
It is important to emphasize that the vast majority of MESs
do not produce immediate symptoms. MESs in cerebral
circulation indicate asymptomatic patients with increased
strokerisk.Nevertheless,correlationofcerebralmicroemboli
with clinical symptoms (stroke or TIA ipsilateral to carotid
stenosis, higher incidence of stroke in patients with cardiac
diseases, neurological complications after angiography, post-
operative neurological complications after CEA, in patients
after CABG) in a number of studies has been shown. In
symptomatic patients, the etiology of neurological deﬁcit
may be elucidated and adequate therapy may be introduced.
Patients with cerebral microembolism have higher cog-
nitive deﬁcits; cumulative eﬀect of embolism is thought to
be the cause. Even minor neuropsychological impairment
should not be underestimated, the presence of an embolic
source should be regarded as the possible cause for cognitive
decline. Imaging techniques (CT scan, MRI, DWI-MRI) can
show “silent” areas of cerebral ischemia. These small and
multiple areas of acute or subacute brain infarction may
occasionally present with clinical features atypical for brain
embolism or will not produce any apparent symptoms [94].
Despite disputable clinical signiﬁcance in certain condi-
tions, the potential beneﬁt of TCD detection of MES remains
substantial.
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